D 6 Clinical trial issues in critical limb ischaemia  by unknown
Clinical Trial Issues in Critical Limb Ischaemia 8237
11. Cheshire N, Wolfe J, Noone 11.1, Davies L, Drummond M. The
economics of femorocrural reconstruction for critical leg
ishemia with and without autologous vein . J VaseSurg 1992;15:
167-175.
12. Hunink MG, Cullen KA, Donaldson Me. Hospital costs of
revacularization procedures for femoropopliteal arterial dis-
ease . J VaseSurg 1994;19: 632-641.
13. Hunink 11.1, Wong J, Donaldson MC, Meyerovitz MF, de Vries J,
Harrington DP. Revascularization for femoropopliteal disease.
JAMA 1995;274: 165-171.
14. Jeans WD, Danton RM, Baird RN, Horrocks M. A comparison of
the costs of vascular surgery and balloon dilatation in lower
limb ischaemic disease. Br J Radio11986; 59: 453-456.
15. Yin D, Baum RA, Carpenter JP, Lmglotz Cp' Pentecost MJ. Cost-
effectiveness of MR angiography in cases of limb-threatening
peripheral vascular disease. Radiology 1995;194: 757-764
16. Gupta SK, Veith FJ. Inadequacy of diagnosis related group reim-
bursement for limb salvage lower extremity arterial reconstruc-
tion. J Vase Surg 1990; 11: 348-357.
17. Stem PH. Occlusive vascular disease of lower limbs: Diagnosis,
amputation surgery and rehabilitation. Am J Phys Med
Rehabilitaion 1988;67: 145-154.
18. Scott HM, Scott WG. Critical leg ischaemia in New Zealand.
Pharmacoeconomics 1994; 6: 149-154.
19. Gupta SK, Veith FJ. Is arerial reconstruction cost-effective com-
pared with amputation. In Greenhalgh RM, Jamison CW,
Nicolaides AN, cds. Limb Salvage and Amputation for Vascular
Disease .. Philadelphia: Saunders, 1988: 447-52.
20. Luther M. Treatment of chronic critical leg ischemia. Ann Chir
Gynaecol 1997;86: 5213).
21. Callow AD, Mackey We. Costs and benefits of prosthetic vas-
cular surgery. Int Surg 1988; 73: 237-240
22. [ohnson BF,Evans L, Drury R, Datta D, Morris-Jones W, Beard
ID. Surgery for limb threatening ischemia: a reappraisal of the
costs and benefits. Eur J Endovasc Surg 1995; 9: 181-188.
23. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does
a new technology have to be to warrant adoption and utiliza-
tion? Tentative guidelines for using clinical and economic eval-
uations. Can Med Assoc J 1992; 146: 473-481.
24. Sculpher 11.1, Michaels J, McKenna 11.1, Minor J. A cost-utility
analysis of laser-assisted angioplasty for peripheral arterial
occlusion. Int J Technol Assessment in Health Care 1996; 12:
104·125.
D6
CLINICAL TRIAL ISSUES IN CRITICAL LIMB
ISCHAEMIA
D 6.1
Introduction
D 6.1.1
Scope
As with Clinical Trial Issues in "Intermitten t
Claudication (B 6, P 5108), this section is not intended
to be exhaustive but rather focuses on selected contro-
versial issues. Similarly, recommendations made here
are usually not based on solid scientific evidence,
which is rare in this area of trial methodology. In
patients with CLI, trials involving surgical or
endovascular techniques as well as drug therapy are
usually relevant. "Trial" in this context is taken to
mean a study designed to investigate the possible effi-
cacy of one treatment modality compared with anoth-
er. This definition of a trial would exclude a purely
descriptive account of a particular treatment as pre-
sented in most publications on new surgical or
endovascular techniques. Trials in CLI are very rarely
performed in the context of a randomised comparison
between a new technique and an established tech-
nique. Therefore, in assessing the efficacy for a new
interventional technique, one usually has to fall back
on historical comparisons with studies describing pre-
vious techniques. The reliability of such comparisons
depends crucially on the accuracy of description, that
is, reporting standards (see later discussion).
The principal threat to patients with CLI as far as
their legs are concerned is failure to relieve ulceration,
gangrene, or rest pain, leading to the need for a major
amputation. Therefore, only trials primarily designed
to look at the efficacy of a new treatment in the context
of limb salvage will be considered. Patients with
chronic CLI also have a higher risk of cardiovascular "
mortality and morbidity (see Epidemiology, Natural
History, Risk Factors, A 2, P 54). The role of meta-
analysis and decision modelling as an alternative is
considered in Economic Aspects of PAD (A 4, P 539).
After a general discussion of the problems involved in
defining entry criteria and outcome response in all tri-
als in patients with CLI, special issues relating to
interventional trials and drug trials are discussed. For
several decades, patients with CLI could be treated
successfully only by surgery. Most published studies
on the treatment of CLI are descriptive accounts of a
particular technique with no comparative group and,
until recently, not using a standardised method of
reporting. Over the last 10 to 15 years, a number of
publications have described endovascular techniques,
a few comparing them in randomised series with sur-
gical alternatives. Trials of pharmacotherapy are even
more recent and usually follow the conventional
methodology of a randornised controlled trial.
There have been no published trials of pharma-
cotherapy versus an interventional treatment in
patients with CLI. This is partly because no pharma-
cotherapy has yet been perceived to be possibly "as
effective as an alternative interventional technique,
although this has never been tested . Such a compara-
tive trial would pose special problems in terms of
deciding appropriate end points because pharma-
cotherapy that may promote healing in a critically
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ischaernic limb may also have a systemic effect in
reducing cardiovascular mortality and morbidity.
Conversely, the benefits of an interventional treatment
are likely to be confined to the leg. Nevertheless, these
three alternative treatment modalities should be prop-
erly compared because, from the patientis point of
view, the ultimate aim and therefore end point is the
same: to avoid mortality and cardiovascular morbidi-
ty while preserving an intact and painless limb. The
current text and recommendations take into account
the outcome of the recent Trans-Atlantic Conference
on Clinical Trial Guidelines in PAOD:Clinical Trial
Methodology,'
D 6.1.2
Trial Design
As in all diseases, ideally trials should be double-
blind, randomised, and compared with placebo or an
existing treatment of proven efficacy. This ideal can
only be approximated in interventional trials.
Similarly trials between different treatment modali-
ties, for example, comparing devices with pharma-
cotherapy, cannot be blinded. However, all trials
involving patients with CLI have common features,
such as issues relating to entry criteria and outcome
assessment. These arc considered in the next two sec-
tions. Another feature that they have in common is
that the new treatment should be assessed against a
background of a standard basic therapy, such as
antiplatelet agents, as described earlier (0 4.3.3,
Pharmacotherapy Other Than Prostanoids, p 5169).
For instance, treatment of concomitant illnesses such
as cardiac failure should continue as well as standard
local treatment.
D 6.2
Entry Criteria for Randomised Trials
In contrast to trials in IC, the principal problem with
CLI is the entry criteria, whereas deciding the relevant
end point is much easier. The latter clearly has to be
some combination of healing of ulcers, relief of rest
pain, and avoiding a major amputation, as well as con-
sideration of general cardiovascular morbidity and
mortality. The problem with deciding entry criteria is
that the risk of continuing tissue necrosis and rest pain
varies widely from patient to patient, and therefore
the risks of requiring a major amputation also vary. It
is also necessary to consider briefly the factors affect-
ing the progression of CLI.
Eur J Vase Endovasc Surg Vol 19 Supplement A, June 2000
D 6.2.1
Progression of CLI
The factors affecting the progression of CLI are dis-
cussed in detail elsewhere (A 2.6, Critical Limb
Ischaemia, p 518). These include the local blood pres-
sure and perfusion, usually measured as Doppler sys-
tolic pressure at the ankle or the toes, and the TCP02 •
Furthermore, a variety of clinical features, including
diabetes and the morphology of the arterial lesion,
affect clinical progression. Some studies have looked
at these variables in relation to the progression of CLI.
Their influence is often dependent on whether a
patient merely has rest pain or has areas of tissue
necrosis as well. For instance, the absolute ankle sys-
tolic pressure is predictive of the need for a major
amputation in patients with rest pain alone, but less so
in patients who also have tissue necrosis.' It is thus
possible to describe a subgroup of patients with CLI,
on the basis of Doppler pressure or the TCP02, in
whom, in the absence of a dramatic improvement in
blood flow, a major amputation is inevitable. It is
therefore possible to limit entry into a trial to those
patients in whom major amputation is almost certain-
ly going to be necessary in the absence of a major
haemodynamic improvement.
Some of the debate over limits of ankle systolic pres-
sure for entry is caused by confusion about the pur-
pose of such measurements. They can be used merely
to establish that the patientis skin necrosis or pain is
predominantly caused by arterial disease, in which
case the cut-off in these measurements can be relative-
ly high. Alternatively, they can be used to predict the
almost inevitable need for a major amputation in the
absence of successful treatment, in which case limits
will need to be much lower. There is no argument that
they should almost certainly be used for the former
purpose, that is, to establish that the patient's symp-
toms are attributable to arterial disease. This can be
important, particularly in the case of rest pain, which
can be caused by a number of nonarterial causes, such
as diabetic sensory neuropathy. The issue of using
these measurements to predict prognosis raises the
controversy between inclusive and exclusive entry cri-
teria, which has already been discussed in the context
of trials in Ie.
D 6.2.2
Inclusivity Versus Exclusivity
Whether an inclusive set of entry criteria should be
used to include a range of patients with different
degrees of disease severity, or a set of exclusive crite-
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ria that defines a small, tight group of patients with
very similar disease and prognosis, is controversial.
The arguments in favour of each approach are more
stark in CLI than in IC Arguments in favour of exclu-
sivityare:
• Patients entered form a homogenous group.
• Patients are clearly defined.
• Differences between treatment and control group in
terms of demographic or other characteristics,
which are known to affect a treatment result, are
largely eliminated.
• At least theoretically, the trial conditions are clearly
defined and should be repeatable with similar
results in other centers.
• The expected outcome in the control group is
almost defined in the entry criteria, that is, limb
loss. Any preservation of limb in the treatment
group is likely to be important.
Arguments in favour of inclusivity are:
• The more inclusive the study, the more it reflects
real life.
• Recruitment is easier, and fewer study centres are
required.
• In practice, if the result of the study is positive, the
new treatment is likely to be applied to all patients
with CLI. It should therefore be demonstrated to be
effective in all patients, unless there is a good rea-
son to exclude a particular subgroup.
There are two other powerful arguments against an
exclusive requirement for entry. If only those patients
are entered who are almost certain to go on to major
amputation in the absence of a dramatic improvement
in blood flow, there is a danger that most patients
entered already have irreversible ischaemic changes.
In such patients, no treatment could possibly succeed
in avoiding amputation. The second argument against
an exclusive entry qualification is that the number of
patients with CLI presenting to even a large vascular
centre is relatively small. With very strict entry crite-
ria, many centres will only be able to enter one patient
per month at best. Such a recruitment rate, with its
attendant need for a large number of centres, raises a
whole new set of problems. A possible set of relative-
ly inclusive entry criteria could be (1) rest pain, ulcers,
or gangrene caused by PAD, (2) an ABPI of less than
0.7 or an ankle toe pressure index of less than 0.4, or,
alternatively, a TCP02 of less than 30 mm Hg.
Repeatedfrom p 5146
Recommendation 74: Trials alld reportillg stalldards
dctinition of critical Iimb ischaemia; ..
A relatively inclusioe entru criterion is favoured, tire
aim being to ensure that tile ulceration, gallgrelle, or
rest pain is indeed caused by peripheral arterial dis-
ease and tltat most would be expected to require a
major amputation toithin tile next 6 months to a
year ill the absence of a significant ltaetnodsjnamic
improucntent. To achieve this, it is suggested to lise
absolute pressures of either
ankle pressure < 5D-70 nun Hg or -
reduced toe pressure (<30-50 111111 Hg) or
reduced TCP02 «3D-50 1I1111 Hg)
Much confusion has arisen in the past from the
entry criteria to a CLI trial being equated with a clini-
cal definition of CLI. This issue is discussed in detail in
Nomenclature, D 1.1 (p 5144), concluding that the
term CLl should be used for routine clinical purposes
to include all patients with ischaernic rest pain and
patients with ischaemic ulcers or gangrene caused by
PAD. This is how the term CLI is used in this docu-
ment. TIghter entry criteria, which may be used for tri-
als of CLI, should not be confused with the broader
clinical definition.
D 6.2.3
Stratification of Patients
As in trials in IC, there are two possible reasons for
stratification:
• To ensure comparability between active and control
groups in terms of demographic or other character-
istics that may affect the response to treatment
• The possibility or probability that a treatment
may be effective only in a subgroup of the total
population
As in trials of claudication, there is no reason to
stratify patients with CLI on the basis of variables that
are not known to affect outcome. Some stratification
will almost certainly be necessary in trials of patients
with CLI. This is because, as mentioned, there is rea-
sonable evidence that some subgroups have a differ-
ent natural history with standard therapy and that
some forms of therapy are more likely to be effective
in some subgroups. For example, the success of many
forms of interventional therapy very much depends
on the site treated and the status of the run-off.
Proximal revascularisations are more likely to be suc-
cessful than distal ones. For the same reason, as well
Em J Vase Endovasc Surg Vol 19 Supplement A, Jun e 2000
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as possibly for other reasons, amputation is more like-
ly to be avoided in a nondiabetic than a diabetic
patient. There is also a suggestion that patients with
diabetes are likely to behave differently in terms of
cardiovascular morbidity and mortality. An alterna-
tive to stratification is simply to perform separate tri-
als, for instance, to exclude diabetic patients in trials of
pharmacotherapy.
Recommendation 104: Stratification in trials of
patients with critical limb ischaemia
Stratification should be considered for:
• patients with ulcers or gangrene (trophic
changes) versus patients with rest pain alone
• diabetic versus nondiabetic patients
• morphology of arterial disease in trials of inter-
ventional therapy, in terms of both the segment to
be treated and the distal'run-of£'
• stratification for entry ankle or toe systolic pres-
sure may be advisable in trials of pharmacothera-
py if the entry criteria are inclusive
• end-stage renal disease (already excluded from
pharmacotherapy trials)
06.3
End Points/Outcome Reporting
06.3.1
Range and Assessment of Possible Primary End Points
Reliefof rest pain
Relief of rest pain may be the principal aim for the
patient, but it is exceedingly difficult to assess objec-
tively what is a purely subjective phenomenon.' The
best that can be achieved is complete relief of pain
without the use of any analgesics. Any end point short
of this is probably too imprecise. In drug trials, this
end point probably has to be assessed when
the patient has been off treatment for a few days to
ensure that the treatment was not merely a powerful
analgesic.
Ulcer healing
In practice, most investigators have found this end
point surprisingly difficult to assess objectively. There
is general agreement that a tendency to healing or
reduction in ulcer size is too difficult to assess objec-
tively and is possibly irrelevant on its own. Total heal-
ing of the ulcer is therefore the best definition of this
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end point, but even this can cause problems. There is
an observer variation in deciding whether an ulcer has
healed, and blinding of the observer is therefore essen-
tial. There is also the problem of variation between
centers in this regard. Only patients with "flat surface"
or "transdermal" ulcers should be admitted.
Ischaemic cracks between the toes or on the heel can-
not be used as measurable end points. Photographic
documentation of ulcer healing has proved in practice
to be unsatisfactory. A possibly useful variation in the
definition of this end point is to use time to complete
healing rather than the number. of healed ulcers at a
particular set time.
Amputation
This is a relatively difficult end point and reflects what
the patient wants to avoid. Only major amputations,
above the mid-forefoot, should be counted, and the
level of amputation should be reported. A healed
minor amputation is little handicap and is often the
best that can possibly be achieved in patients who
already have gangrene of the digits. Blinding of the
observer, that is, the person making the decision to
advise amputation, is desirable because there is prob-
ably variation in the level of disease and handicap at
which a decision is made to advise amputation.
Cardiouascular morbidity and total mortality
Depending on the entry criteria, between 10% and
30% of patients with CLI will have a major nonfatal or
fatal cardiovascular event over 6 to 12 months. This
may be affected by a local interventional therapy, both
positively and negatively. There may be a mortality or
morbidity associated with the intervention.
Alternatively, it is conceivable that successful inter-
vention may decrease overall morbidity or morality. A
successful pharmacological treatment for CLI also
may have a positive effect on cardiovascular morbidi-
ty and mortality. Therefore, these crucial outcomes
also need to be incorporated into the primary end
point.
06.3.2
Choice of Primary End Point
The above end points all relate to clinical outcome,
which is probably appropriate for a primary end
point. Technical outcome in interventional therapies
should not be a primary end point but should be
recorded as a secondary end point. The patency of a
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new graft or a re-opened segment using endovascular
techniques is clearly relevant, but in the absence of a
clinical improvement, it would be inappropriate to
record it as a primary end point. A hierarchy of possi-
ble end points is suggested.
Recommendation 105: Primary end points in trials
in patients with critical limb ischaemia
The primary end point should be event-free sur-
vival. Nonfatal events include major amputation,
nonhealing of ischaemic ulcers, and ischaemic
pain, myocardial infarction, and ischaemic stroke.
In addition, the individual components of this end
point should also be reported.
D 6.3.3
Timing of Outcome Reporting
The minimum period of observation should be 6
months. Any treatment benefit that can only be
demonstrated over a shorter period is probably not
worthwhile. Longer follow-up is desirable and should
not be a particular problem in trials of interventional
therapy because there is no continuing trial treatment.
In trials of pharmacotherapy, however, there is a prac-
tical limit to how long the treatment can be continued;
with all the close monitoring that this requires, a treat-
ment period of more than a year is probably not prac-
tical.
D 6.3.4
Quality of Life Assessment
A validated quality of life assessment may be a sec-
ondary end point. Superficially, it may be thought
that with major clinical end points such as amputa-
tion, a quality of life assessment is less important.
However, this is probably incorrect. Many patients
find that their quality of life is considerably
improved after a healed major amputation compared
with continuous rest pain or ulceration, which they
may have had for several months before the amputa-
tion. Limb function is an important aspect of CLI,
and changes in limb function before and after treat-
ment should be recorded.
Critical Issue 47: Validated disease-specific quality
of life instrument as a primary end point
There is a need for a validated quality of life instru-
ment as a possible primary end point in the treat-
ment of critical limb ischaemia, because none cur-
rently exists, and comorbidities tend to obscure the
impact of treatment.
D 6.3.5
Economic Evaluation
This is particularly important in this area because of
the major costs involved in treating CLI and in sup-
porting patients who have had an amputation.
Various methodologies have been used to calculate
the cost-effectiveness of various types of intervention
in CLI, and the complicated technical issues raised are
discussed in more detail in 0 5.1.2, Costs of Treatment
for Critical Limb Ischaemia, p 5232). The methodology
for cost analysis in a trial should be set out in the pro-
tocol and should be prospective. Patient groups
should be compared on an intent-to-treat basis, and
costs should be computed over the entire duration of
the study. The outcome of the cost analysis can be set
out much more meaningfully in CLI than in trials of
IC, for example, by calculating the cost of saving one
fully functional leg for 1 year.
Recommendation 106: Selected secondary end
points in trials in patients with critical limb
ischaemia
Quality of life instruments ideally should be used
in all trials.
The methodology for cost analysis in the trial
should be set out in the protocol and should be
prospective.
Changes in limb function before and after
treatment
If the primary end point is a composite end point,
the components should be evaluated individually
as secondary end points.
If not used as primary end points, cardiovascular
morbidity and mortality as well as total mortality
should be assessed individually as secondary end
points to ensure the collection of appropriate safety
information.
06.4
Special Issues Relating to Interventional Trials
Comparative trials of interventional therapy, either
surgical or endavascular, have a number of inherent
problems that do not exist in trials of pharmacothera-
py. This is undoubtedly one reason why comparative
trials of interventional therapy have been rare.
D 6.4.1
Operator Variability
The delivery of the intervention cannot be standardised
in the same way as a medication. Not only is the tech-
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nical skill of the operator crucial, but often it is impos-
sible to use the same operator, even within a single cen-
tre, to deliver the two alternative therapies. For
instance, although the same surgeon can perform an in
situ and a reversed vein bypass, if the comparison is
between a surgical bypass and an endovascular proce-
dure, then different operators will be involved. The fact
that an operator is required at all makes blinding of the
treatment delivery impossible. The problem is com-
pounded by the fact that in a multi-centre trial, a num-
ber of different operators, with differing skills, will be
required. This also raises the issue of the applicability of
an interventional trial result to general practice.
Frequently, a new procedure is performed by an
enthusiast who has spent considerable time and effort
in developing that teclmique. Results are likely to be
much superior to those that would be achieved by his
or her colleagues who try to adopt the technique.
There are many examples of initial results with a new
technique from a particular centre being far superior
to the results subsequently recorded with the same
teclmique in regional or national audits.
06.4.2
Importance of Additional Variables in the Entry Criteria
In intervention trials, the local morphology of the lesion
to be treated is of paramount importance in determin-
ing the result. In general, reconstruction of proximal
arteries will be more durable than reconstructions of
distal arteries. Run-off morphology also has to be con-
sidered, because, even though the treated lesion may be
situated in the femoral artery, there is a great difference
between finding just collaterals or three patent vessels
at the crural level. It is essential to define these variables
in the trial and either stratify the patients accordingly or
only include patients with particular characteristics (see
Recommendation 107, p 5242).
06.4.3
Adjuvant Pharmacotherapy in Clinical Trials
There has been an increasing tendency to try to
improve the results of interventional treatment by
some form of adjuvant pharmacotherapy to prevent
both early failure attributable to thrombosis and later
failures caused by neointimal hyperplasia. If a partic-
ular adjuvant therapy, for instance, full anticoagula-
tion immediately after stent placement, has been
shown to be probably beneficial, then it should be
applied as background treatment to all trial patients.
Problems arise when evidence of the efficacy of adju-
vant therapy is inconsistent, for instance, in the use of
antiplatelet drugs long-term after vein bypass grafts.
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The principle of applying all standard procedures that
may improve the result to both the treatment and the
control group also applies to issues such as graft sur-
veillance, which has been shown to improve long-
term patency.
Recommendation 107: Reporting standards in inter-
ventional trials in patients with critical limb
ischaemia
The recommendations of the committee on
Reporting Standards of the SVS/ISCVS, and in the
case of new devices the standards of the
Technology Assessment Committee of the SCVIR,
should be adopted where appropriate in trials
involving patients with CLI.
D 6.5
Special Issues Relating to Drug Trials in ell
06.5.1
Patients Entered
The issues discussed under Entry Criteria (0 6.2, P
S238) apply here. In virtually all trials of stand-alone
pharmacotherapy for treatment of CLI, only. those
patients have been entered who already had some
form of interventional treatment-often several-that
have all failed, or in whom interventional treatment is
technically impossible. Therefore, the patients entered
tend to be at an end-stage of CLI. This will be further
exacerbated if tight inclusion criteria are used in terms
of Doppler systolic pressure or TCP02• The net result
is often that most patients entered into these trials are
probably beyond salvage by any therapy. Inclusion of
patients who have not reached end-stage CLI would
be of importance, although comparative trials
between interventions and pharmacotherapy are
probably not yet appropriate.
06.5.2
Analysis of Secondary Interventions
Although suitability for some form of reconstructive
surgery is usually an exclusion criteria in these trials,
in practice some patients who deteriorate during the
period of the trial do undergo some form of interven-
tionaI treatment. The explanation is probably that the
interventional treatment is high risk, and therefore the
doctor in charge preferred to avoid it in the hope that
a pharmacological intervention may work. However,
when this does not occur, then a last-resort procedure
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is performed. Another explanation may be that varia-
tion exists between surgeons and centres concerning
the suitability of a specific lesion for intervention.
Such circumstances can cause considerable difficulty
in analysing the outcome of the trial on an intention-
to-treat basis. It is conceivable that the patients ran-
domised to the active drug deteriorate more quickly
than the control group. Therefore, more patients in the
active group will receive some form of interventional
therapy, and if this is successful, then on an intention-
to-treat basis, the active drug could wrongly appear to
be effective.
Alternatively, it is possible that the test drug pro-
vides no benefit alone but is an effective adjuvant to
interventions. If a large proportion of patients under-
go some form of intervention, then a positive result to
the trial could misleadingly suggest that the drug is
effective on its own. Subgroup analysis considering
specifically the patients not undergoing secondary
intervention is, under these circumstances, necessary.
D 6.5.3
Other Issues
Cardiovascular events
Drug therapy for CLI is usually administered system-
ically and, for reasons already explained, possibly
may also benefit the patient in terms of nonfatal or
fatal cardiovascular events. However, the contrary
also may be true, and the drug treatment may precip-
itate cardiovascular events. The issue of stopping rules
in the event of an excess in cardiovascular events in
one of the trial groups is an important issue in drug
trials.
Effect ill coniraiaieral lcg
The systemic effect of drug treatment also raises the
issue of how to deal with a change in the contralateral
leg. (This can clearly be ignored when looking at inter-
ventional therapy in one leg.) Although entry into a
drug trial should be on the basis of an index leg,
changes in the contralateral side during the course of
the treatment cannot be ignored. The primary clinical
end points described in D 6.3.2, Choice of Primary End
Point, p S240} must apply to both legs. If a drug treat-
ment heals the ulcer on the index leg, but during the
same period the patient develops an ulcer on the other
leg, then the drug treatment cannot be considered to
have been successful.
Sideeffects
Many of the drugs used in trials of pharmacotherapy
in CLI have obvious, albeit not dangerous, side effects.
For instance, prostacyclin analogs often produce
flushing, headaches, or nausea. This raises the ques-
tion of the completeness of the blinding of the investi-
gator or observer.
Active drug control
Active drug control may be considered if the com-
parator drug has consistently been shown to be supe-
rior to placebo and if the magnitude of its effect is gen-
erally accepted by the medical community.
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